Deep Dive Ticker Tape
Article published Mar 11, 2026. Prices below use latest available snapshots.
BNTX Price Structure
Loading chart…
Loading timeframes…
Conviction: Medium Status: Researching -- RSI 23.3, price $83.89, extreme oversold, -23.3% 30D
Quick Snapshot
| Signal | Reading |
|---|---|
| Overall | 🟢 RSI 23.3 (computed) -- extreme oversold. Price $83.89, -17.4% 7D, -23.3% 30D, -12.6% 3M. SMA20 ~$105.83 -- price -20.7% below SMA. Capitulation-level selling. |
| Moat | Narrow (mRNA platform, oncology pipeline) |
| Key insight | BNTX is in extreme oversold territory -- RSI 23.3 with a -23.3% 30D crash. Price is -20.7% below SMA and -32.4% from 52wk high. The mRNA platform that powered COVID vaccines is being redirected toward oncology (personalized cancer vaccines, BNT327 antibody). Cash-rich ($18B+ at last report). The selloff appears driven by COVID revenue cliff concerns and oncology pipeline uncertainty. At these levels, the cash alone may provide downside support. |
Action Matrix
| Action | Level | Why |
|---|---|---|
| Current | 🔍 Research | Extreme oversold but need to understand catalyst for selloff |
| Entry Zone | $75 - $90 | Current $83.89 -- IN ZONE |
| Stop-Loss | $65 (-22%) | Below multi-year support |
| Target | $120 (+43%) | Recovery toward SMA levels |
Extended analysis
Price Data
| Stock | Price | 1D | 7D | 30D | 3M | 52wkHi | RSI | Status | Action |
|---|---|---|---|---|---|---|---|---|---|
| BNTX | $83.89 | -- | -17.4% | -23.3% | -12.6% | -32.4% | 23↓ | 🟢 Extreme Oversold | 🔍 Research |
Company Overview
One-Liner
BioNTech is a German biotech focused on mRNA therapeutics, best known for co-developing the Pfizer-BioNTech COVID vaccine, now pivoting to oncology.
Business Model
| Question | Answer |
|---|---|
| What they sell | mRNA vaccines (COVID), oncology pipeline (personalized cancer vaccines, BNT327) |
| Who pays | Governments (COVID vaccines), eventually patients/insurers (oncology) |
| Revenue model | Product sales (COVID), royalties, collaboration payments |
| How sticky | Low for COVID (declining); potentially high for oncology if approved |
Bull Case
- Extreme RSI 23.3 -- Capitulation-level selling on a cash-rich biotech.
- $18B+ cash -- Provides years of runway and downside floor.
- Oncology pipeline -- Personalized cancer vaccines, BNT327 blockbuster potential.
- mRNA platform optionality -- Infectious disease beyond COVID + oncology + rare disease.
- Down trend but golden cross still intact -- SMA50 and SMA200 near parity.
Bear Case
- COVID revenue cliff -- Revenue declining 50%+ as pandemic demand fades.
- Oncology unproven at scale -- Pipeline risk; phase 3 readouts needed.
- -20.7% below SMA -- No sign of stabilization yet.
- Competition from Moderna -- mRNA competitor with similar pivot.
- Cash burn accelerating -- R&D spend rising as revenue falls.
Thesis Killers
- Major oncology trial failure
- Cash burn rate exceeds expectations
- mRNA platform shows safety concerns
Research Log
| Date | Update |
|---|---|
| 2026-03-11 | Created. RSI 23.3 extreme oversold. $83.89. -23.3% 30D. Research. |
The Gold
Key Discoveries
| Discovery | Implication |
|---|---|
| RSI 23.3 -- extreme oversold for a cash-rich biotech | Either capitulation entry or catching a falling knife |
| -23.3% 30D, -17.4% 7D -- accelerating selloff | Something specific may have triggered this -- need to research |
| $18B+ cash vs ~$20B market cap | Cash provides meaningful downside floor |
Open Questions
- What specifically caused the -23.3% 30D crash? (Trial data? Revenue guidance? Sector rotation?)
- What is current cash burn rate?
- What are next oncology pipeline readout dates?
- Is Moderna (MRNA) selling off similarly? (Sector-wide vs company-specific?)
- What is BNT327 status and blockbuster potential?
Sources
- Fundamentals figures: company-reported results (quarterly/annual filings) as available at the artifact date; predates the desk's EDGAR reconciliation gate — figures not re-verified after publication.